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Abstract
BACKGROUND 
Gastric cancer is the fifth most diagnosed cancer worldwide and the third most 
common cause of cancer-related death. In recent decades, increasing application 
of next-generation sequencing has enabled detection of molecular aberrations, 
including fusions. In cases where tissue is difficult to obtain, cell-free DNA 
(cfDNA) is used for detecting mutations to identify the molecular profile of 
cancer. Here, we report a rare case of EGFR-SEPT14 fusion detected from cfDNA 
analysis in a patient with gastric cancer.
CASE SUMMARY 
A 49-year-old female diagnosed with advanced gastric cancer in July 2019 
received capecitabine and then combination chemotherapy of ramucirumab and 
paclitaxel, but ascites was detected. The therapy was switched to nivolumab, but 
disease progression was observed on a positron emission tomography/computed 
tomography scan in May 2020. Therapy was discontinued, and cfDNA next-
generation sequencing was immediately evaluated. All genomic variants, inclu-
ding fusions, were analyzed from cfDNA. The following somatic alterations were 
detected from the patient’s  cfDNA: an APC frameshift  mutation 
(NM_000038.5:c.6579del, p.V2194fs) with variant allele frequency of 0.5%, an 
EGFR amplification with a copy number of 17.3, and an EGFR-SEPT14 fusion with 
variant allele frequency of 45.3%. The site of the fusion was exon 24 of EGFR fused 
to exon 10 of SEPT14. The fusion was in-frame and considered to be proto-
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oncogenic. Although the patient refused to continue therapy, we suggest that 
EGFR-targeted therapies be tried in such future cases.
CONCLUSION 
The expanded applications of the cfDNA assay may open a new horizon in 
treatment of patients with advanced gastric cancer.
Key Words: Gene fusion; Cell-free DNA; Liquid biopsy; Gastric cancer; EGFR tyrosine 
kinase inhibitor; Case report
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Core Tip: In recent decades, increasing application of next-generation sequencing has 
enabled detection of molecular aberrations, including fusions. In cases where tissue is 
not easily obtainable, cell-free DNA is used for detecting mutations to determine the 
molecular profile of cancer. In this study, we report the first case of EGFR-SEPT14 
fusion detected from next-generation sequencing analysis of cell-free DNA from a 
patient with advanced gastric cancer. We suggest expanded applications of the cell-free 
DNA assay regardless of cancer type, which may open a new horizon in treatment of 
patients with advanced gastric cancer.
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Gastric cancer is the fifth most diagnosed cancer worldwide with a particularly high 
incidence in East Asia and the third most common cause of cancer-related death[1]. 
Curative surgery is the primary treatment of choice, but systemic chemotherapies are 
used for patients with metastatic or unresectable advanced or recurrent gastric cancer. 
Because systemic chemotherapies are nonspecific and can cause serious adverse 
effects, development of molecular targeted drugs has been attempted to improve 
outcomes in patients with gastric cancer.
In recent decades, increasing application of next-generation sequencing (NGS) has 
enabled detection of molecular aberrations such as copy number gains or losses, 
somatic mutations, and gene fusions. For cases where tissue is not easily obtainable, 
cell-free DNA (cfDNA) is used for detecting mutations to determine the molecular 
profile of cancer[2]. Successful identification of oncogenic gene fusions can aid in 
diagnosis and molecular treatment of patients[3]. Here, we report a rare case of EGFR-
SEPT14 fusion detected from cfDNA analysis in a patient with gastric cancer.
CASE PRESENTATION
Chief complaints
A 49-year-old female patient had been treated for advanced gastric cancer (AGC) with 
chemotherapy. After therapy, she expressed whole body pain, especially on the left 
side of the pelvis.
History of present illness
This patient had been diagnosed with AGC in July 2019. The pathological diagnosis 
indicated signet ring cell carcinoma. While receiving her first round of chemotherapy 
with capecitabine, the patient developed acute pyelonephritis and hydronephrosis in 
both kidneys, leading to a suspicion of periureteral metastases. Therefore, the patient 
started a new regimen of combination chemotherapy with ramucirumab and 
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paclitaxel. However, ascites was observed after two cycles of chemotherapy. The 
treatment was switched to nivolumab. After five cycles, an abdominopelvic computed 
tomography scan was performed in April 2020 that showed improvement in 
peritoneal carcinomatosis compared to an image from February 2020. She received 
seven cycles of nivolumab, but progressive disease was observed by the positron 
emission tomography/computed tomography scan, and other therapeutic options 
were needed to be discussed.
History of past illness
The patient did not have any other medical history beyond AGC.
Personal and family history
The patient reported a family history of gastric cancer in her grandfather.
Physical examination
Physical examination revealed pain on the left side of the pelvis.
Laboratory examinations
Blood analysis revealed mild leukocytosis (14 × 109/L) with low hemoglobin (10.3 
g/dL). Platelet count was in the normal range. Serum C-reactive protein was increased 
at 181 mg/L (normal range, 0.1-6.0 mg/L).
Imaging examinations
A positron emission tomography/computed tomography scan obtained in May 2020 
revealed bone, multiple nodal, and right lateral abdominal wall soft tissue metastases 
after the patient had received seven cycles of nivolumab. The therapy was discon-
tinued, and cfDNA NGS was performed immediately.
Further genetic diagnostic work-up 
For genetic testing, the patient provided informed written consent for specimen 
collection and genetic analysis. This study was approved with a waiver of informed 
consent by the Institutional Review Board of Gangnam Severance Hospital, Seoul, 
Korea (IRB No. 3-2020-0268).
cfDNA was extracted using the MagMAX Cell-Free Total Nucleic Acid Kit (Thermo 
Fisher Scientific, Waltham, MA, United States). A DNA library was constructed with 
the AlphaLiquid®100 kit (IMBDx Inc., Seoul, Korea), which was designed to include 
intronic regions of target genes. Hybrid-capture-selected libraries were sequenced to a 
mean coverage of 14237x (cfDNA) and 735x (DNA) on an Illumina NextSeq-550 
(Illumina, San Diego, CA, United States). GeneFuse was used to detect fusions[4], and a 
Genome Reference Consortium Human Build 38 was used for variant interpretation. 
All genomic variants, including fusions, were analyzed from cfDNA. Because of the 
patient’s family history, the presence of germline mutation was tested in parallel for 
the following genes: APC, ATM, BRCA1, BRCA2, CDH1, CDK4, CDKN2A, and MLH1. 
No germline mutations were detected from the genomic DNA. Somatic alterations 
detected from the cfDNA were an APC frameshift mutation (NM_000038.5:c.6579del, 
p.V2194fs) with variant allele frequency of 0.5%, an EGFR amplification with a copy 
number of 17.3, and an EGFR-SEPT14 fusion with variant allele frequency of 45.3% 
(Figure 1A). Because the EGFR and SEPT14 genes are closely located on chromosome 
7, we tested 50 normal healthy controls with the same panel and confirmed that the 
fusion detected in the patient was a true positive. We also confirmed EGFR-SEPT14 
fusion by complementary DNA sequencing, which was processed using the patient’s 
cell-free RNA extracted by MagMAX Cell-Free Total Nucleic Acid Kit. The site of 
fusion was exon 24 of EGFR fused to exon 10 of SEPT14 (Figure 1B). The fusion was in-
frame and considered to be proto-oncogenic.
FINAL DIAGNOSIS
The final diagnosis of the present case was EGFR-SEPT14 fusion in AGC.
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Figure 1 EGFR-SEPT14 fusion. A: Genomic fusion of EGFR exon 24 with exon 10 of SEPT14; B: RNA sequencing analysis of the EGFR-SEPT14 fusion.
TREATMENT
The patient refused further treatment.
OUTCOME AND FOLLOW-UP
The patient could have tried EGFR targeted therapy such as erlotinib, which has been 
used in other types of carcinomas with EGFR-SEPT14 fusion[5], but she refused further 
treatment and passed away about 1 month after discontinuation of nivolumab.
DISCUSSION
EGFR1 (EGFR; ErbB1; HER1) is one of four transmembrane growth factor receptor 
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proteins that constitute the EGFR family of receptor tyrosine kinases[6]. Activation of 
EGFR leads to cell proliferation, differentiation, motility, and metastasis[7]. SEPT14 is a 
member of a highly conserved septin family of guanosine 5’-triphosphate-binding 
cytoskeletal proteins with multiple cellular functions, such as membrane transport, 
apoptosis, cell polarity, cell cycle regulation, cytokinesis, and oncogenesis[8]. Among all 
septins, SEPT14 shows the highest mutation frequency in skin cancer followed by 
SEPT9 exhibiting high mutation frequency in stomach cancer[9].
The EGFR-SEPT14 fusion was first reported in glioblastoma in which the site of 
fusion was the tyrosine kinase domain of EGFR and the coiled-coil domain of SEPT14. 
The EGFR-SEPT14 fusion is the most frequent functional gene fusion in human 
glioblastoma[10]. The EGFR-SEPT14 fusion was also identified in tissue from salivary 
gland secretory carcinoma using fluorescence in situ hybridization. That previous case 
indicated that a tumor harboring this fusion would be sensitive to EGFR inhibitors[11]. 
Recently, the EGFR-SEPT14 fusion was reported in colorectal adenocarcinoma by 
using a comprehensive NGS assay on tumor samples[5].
In the present study, the tissue biopsy of the patient was difficult. Therefore, we 
used a comprehensive NGS assay with a sample of cfDNA from the patient. We 
identified an EGFR-SEPT14 fusion in AGC. To our knowledge, this is the first case of 
EGFR-SEPT14 fusion identified in a cfDNA sample from an AGC patient. The patient 
went through unusually rapid disease progression, and this progression might have 
been caused by the fusion mutation. Unfortunately, because the patient refused to 
continue therapy, we could not determine whether the EGFR-SEPT14 fusion 
responded to EGFR targeted therapies, such as tyrosine kinase inhibitors. However, 
the use of such therapies might have been effective in AGC with an EGFR-SEPT14 
fusion because there was a report of a patient with colorectal cancer with an EGFR-
SEPT14 fusion treated with erlotinib therapy. The fusion site reported in that study is 
the same as that in the present study, and the patient was administered erlotinib 
therapy to which the EGFR-SEPT14 fusion is known to be sensitive[10]. However, soon 
after treatment, an EGFR variant III was detected and can result in resistance to 
erlotinib[5]. To confirm the treatment effect and disease progression in AGC, further 
studies are needed.
Nevertheless, detection of genomic fusion by the well-established cfDNA NGS 
assay confirmed that cfDNA can serve as an alternate source for detecting gene 
aberrations, including fusions. Furthermore, EGFR-SEPT14 fusion has been reported in 
various types of cancer. Therefore, expanded applications of cfDNA assays should be 
considered regardless of cancer type. We also suggest that genomic variants including 
fusions can be therapeutic targets in AGC, which may open a new horizon in 
treatment.
CONCLUSION
To the best of our knowledge, this is the first case of an EGFR-SEPT14 fusion identified 
in a cfDNA sample from a patient with AGC. Detection of genomic fusion by the well-
established cfDNA NGS assay confirmed that cfDNA can serve as an alternate source 
for detecting gene aberrations, including fusions. Successful identification of genomic 
variants, including fusions, from cfDNA can aid in diagnosis and molecular treatment 
of patients with AGC.
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